High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 3, 2010, Pages 116-120

  Saleh, A J M ^a   Al Mohareb, Fahad ^a   Al Rabiah, Fahad ^a   Chaudhri, Naeem ^a   Al Sharif, Fahad ^a   Al Zahrani, Hazzaa ^a   Mohamed, Said Yousuf ^a   Patel, Moosa ^a   Rasheed, Walid ^a   Nurgat, Zubeir ^a   Bakr, Mohammad ^a   Ahmed, Shad ^a   Zaidi, Syed ^a   Nassar, Amr ^a   Ibrahim, Khaled ^a   Al Abdely, Hail ^a   Aljurf, Mahmoud ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; PRODRUG; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; KIDNEY DYSFUNCTION; MAINTENANCE THERAPY; MALE; NEUTROPENIA; OUTPATIENT; OUTPATIENT CARE; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 79551651772     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.116     Document Type: Article

References (26)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J infect Dis. 1986 Mar;153(3):478-88.
2. Aljurf MD, Zaidi SZ, el Solh H, Hussain F, Ghavamzadeh A, Mahmoud HK, Shamsi T, Othman TB, Sarhan MM, Dennison D, Ibrahim A, Benchekroun S, Chaudhri N, Labar B, Horowitz M, Niederwieser D, Gratwohl A. Special issues related to hematopoietic SCT in the eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant.2009; 43: 1-12.
3. Bernd S, Raleigh AB, Robert CH, Chris D, Michael B. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997; 90(6): 2502-2508.
4. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, Spielberger R, Nakamura R, Forman SJ, Zaia JA, Diamond DJ. Impact of donor CMv-status on viral infection and recon stitution of multi-infection CMv-specific T-cells in CMv-positive transplant recipients. Blood. 2009;113: 6465-6476.
5. Benson CA, Kaplan JE, Masur H, Pau A, and Holmes KK. Treating Opportunistic infections among Hiv-infected adults and adolescents. CDC's Morbidity and Mortality Weekly report (MMWr) 53(rr15): 1-112. December 17, 2004. available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htmwww.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm
6. Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou g, Carratalà J, Torre-Cisneros J, Pahissa A; ReSiTra. valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin infect Dis. 2008; Jan 1;46(1): 20-7.
7. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; valganciclovir Solid Organ Trans-plant Study group. efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004; 4:611-620.
8. Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107(7):3002-3008.
9. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P; infectious Diseases Working Party of the european group for Blood and Marrow Transplantation. randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159-1164.
10. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, Löwenberg B, Cornelissen JJ. Increased transplant-related morbidity and mortality in CMv-seropositive patients despite highly effective prevention of CMv disease after allogeneic T-cell-depleted stem cell transplantation. Blood.2000;95(7):2240-2245.
11. Schmidt GM, Horak Da, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalo-virus pulmonary infection in recipients of allogeneic bone marrow transplants. N engl J Med. 1991; 324:1005-11.
12. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevensayers T, Flowers ME, Cunningham T, Corey L. late cytomega-lovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407-414.
13. Goodrich JM, Mori M, Gleaves Ca, Du Mond C, Cays M, Ebeling DF, Buhles WC, Dearmond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N engl J Med. 1991; 325:1601-7.
14. Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kobayashi T, Takasugi K, Iseki T, Tojo A, Asano S. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation. Bone Marrow Transplant (2008) 41, 371-376.
15. Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009 Jun;15(6):730-40.
16. Raymund RR, Carlos VP. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert rev antiinfect Ther. 2004;2(1):27-42.
17. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV and CMv seropositive volunteers. Clin Pharmacokinet. 1999 aug;37(2):167-176.
18. Freeman RB. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. expert Opin Pharmacother. 2004 Sep;5(9):2007-16.
19. Marshall BC, Koch WC. Antivirals for cytomeg-alovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs. 2009;11(5):309-21.
20. Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gilvernet S, Lloberas N, Pou L, Peraire C, Grinyó JM. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob agents Chemother. 2009 nov; 53(11):4816-24.
21. Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, locatelli F, Falda M. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl infect Dis.2007;9:102-107.
22. Heagy W, Crumpacker C, lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin invest. 1991;87:1916-1924.
23. Bowden RA, Digel J, Reed EC, Meyers JD. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J infect Dis. 1987;156:899-903.
24. Li Cr, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of Hla-restricted cytomegalovirus-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMv disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971-1979.
25. Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto g, Harada n, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; Fukuoka Blood and Marrow Transplant group (FBMTg). Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic stem cell transplant recipients. Int J Hematol. 2009 Mar;89(2):231-237.
26. Bacigalupo A, Tedone E, Sanna MA, Moro F, van lint MT, Grazi G, Balestreri M, Frassoni F, Occhini D, Gualandi F, et al. CMv infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Hematologica. 1992;77:507-513.